Notícias e Atividades da Quince Therapeutics

Quince Therapeutics é uma empresa listada sob o símbolo CRTX (US).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Quince Therapeutics

• Dirk Thye, Chief Executive Officer and Director
• Rajiv Patni, Director
• David Lamond, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da Quince Therapeutics.

Quince Therapeutics possui 2.048 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Siemens Healthineers (Alemanha) e Optum (Estados Unidos).

Popular M&A news in Saúde

• Accolade and Accolade have announced they will merge  (publicado em 9 de abril de 2025)..
• Solace Health acaba de anunciar uma arrecadação de fundos de 60 milhões de dólares. (publicado em 4 de abril de 2025).
• Navina acaba de anunciar uma arrecadação de fundos de 55 milhões de dólares. (publicado em 30 de março de 2025).

Outros contatos sugeridos na indústria do Saúde

• Paulo Junqueira Moll - Chief Executive Officer da Rede D'Or Sao Luiz
• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Bryan Roberts - Director da Included Health

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de Quince Therapeutics

• Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference | Quince Therapeutics
• Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results | Quince Therapeutics
• Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference | Quince Therapeutics
• Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board | Quince Therapeutics
• Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting | Quince Therapeutics
• Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research | Quince Therapeutics
• View more press releases Close

Redes sociais sobre Quince Therapeutics

• Quince Therapeutics na Wikipedia, Google News e Yahoo Finance
• Quince Therapeutics na LinkedIn, Twitter e YouTube